Peer-reviewed journals rejected their followup study on the 2023-2024 formulation of mRNA vaccines against the JN.1 variant of SARS-CoV-2, which found their "low level of protection" was offset by the ...

Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the ...

In today's Morning Rounds newsletter, RFK Jr.'s latest theory about vaccines, how sweeping FDA layoffs could impact drug ...

NIH reversed course on its policy barring scientists from attending scientific conferences and meetings without permission, ...

Robert F Kennedy Jr's controversial views on vaccines were on display this week during an interview with CBS News in which he ...

A tenet of virology is that you go after one of the proteins on the surface that generates a good immune response, and that’s what you target. This principle has withstood the test of time because ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

In the wake of dramatic cuts to US Department of Health and Human Services (HHS) staff, cutbacks for state public health ...